Idorsia AG Aktie

Idorsia Ltd is a biopharmaceutical company based in Switzerland, dedicated to the discovery, development, and commercialization of innovative medicines that address significant unmet medical needs. The company maintains a diverse clinical development pipeline, with therapeutic focuses spanning central nervous system (CNS), cardiovascular, and immunological disorders, as well as various orphan diseases. Idorsia engages in several strategic collaborations: A partnership with Janssen Biotech Inc. for the joint development and commercialization of aprocitentan and its related compounds or products. A licensing agreement with Mochida Pharmaceutical covers the supply, co-development, and co-marketing of daridorexant. The company collaborates with Hoffman-La Roche Inc. to develop and market compounds within the field of cancer immunotherapy. An alliance with Antares Pharma, Inc. focuses on the creation of a self-administered drug delivery system for Selatogrel. A partnership with Neurocrine Biosciences, Inc. is in place for the development and commercialization of ACT-709478, an epilepsy treatment currently in Phase II clinical trials. Idorsia Ltd was founded in 2017 and its corporate headquarters are situated in Allschwil, Switzerland.